IBDEI2V3 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45652,1,3,0)
 ;;=3^Chronic Embolism/Thrombosis Unspec Vein
 ;;^UTILITY(U,$J,358.3,45652,1,4,0)
 ;;=4^I82.91
 ;;^UTILITY(U,$J,358.3,45652,2)
 ;;=^5007941
 ;;^UTILITY(U,$J,358.3,45653,0)
 ;;=I25.9^^172^2275^8
 ;;^UTILITY(U,$J,358.3,45653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45653,1,3,0)
 ;;=3^Chronic Ischemic Heart Disease,Unspec
 ;;^UTILITY(U,$J,358.3,45653,1,4,0)
 ;;=4^I25.9
 ;;^UTILITY(U,$J,358.3,45653,2)
 ;;=^5007144
 ;;^UTILITY(U,$J,358.3,45654,0)
 ;;=D68.9^^172^2275^9
 ;;^UTILITY(U,$J,358.3,45654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45654,1,3,0)
 ;;=3^Coagulation Defect,Unspec
 ;;^UTILITY(U,$J,358.3,45654,1,4,0)
 ;;=4^D68.9
 ;;^UTILITY(U,$J,358.3,45654,2)
 ;;=^5002364
 ;;^UTILITY(U,$J,358.3,45655,0)
 ;;=D68.8^^172^2275^10
 ;;^UTILITY(U,$J,358.3,45655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45655,1,3,0)
 ;;=3^Coagulation Defects,Other Spec
 ;;^UTILITY(U,$J,358.3,45655,1,4,0)
 ;;=4^D68.8
 ;;^UTILITY(U,$J,358.3,45655,2)
 ;;=^5002363
 ;;^UTILITY(U,$J,358.3,45656,0)
 ;;=D68.318^^172^2275^11
 ;;^UTILITY(U,$J,358.3,45656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45656,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
 ;;^UTILITY(U,$J,358.3,45656,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,45656,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,45657,0)
 ;;=Z79.01^^172^2275^12
 ;;^UTILITY(U,$J,358.3,45657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45657,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,45657,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,45657,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,45658,0)
 ;;=Z79.02^^172^2275^13
 ;;^UTILITY(U,$J,358.3,45658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45658,1,3,0)
 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,45658,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,45658,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,45659,0)
 ;;=D68.62^^172^2275^14
 ;;^UTILITY(U,$J,358.3,45659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45659,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,45659,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,45659,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,45660,0)
 ;;=I73.9^^172^2275^15
 ;;^UTILITY(U,$J,358.3,45660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45660,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,45660,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,45660,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,45661,0)
 ;;=Z86.79^^172^2275^16
 ;;^UTILITY(U,$J,358.3,45661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45661,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,45661,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,45661,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,45662,0)
 ;;=Z86.711^^172^2275^17
 ;;^UTILITY(U,$J,358.3,45662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45662,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,45662,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,45662,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,45663,0)
 ;;=Z86.718^^172^2275^18
 ;;^UTILITY(U,$J,358.3,45663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45663,1,3,0)
 ;;=3^Personal Hx of Venous Thrombosis/Embolism
 ;;^UTILITY(U,$J,358.3,45663,1,4,0)
 ;;=4^Z86.718
 ;;^UTILITY(U,$J,358.3,45663,2)
 ;;=^5063475
 ;;^UTILITY(U,$J,358.3,45664,0)
 ;;=Z95.2^^172^2275^19
 ;;^UTILITY(U,$J,358.3,45664,1,0)
 ;;=^358.31IA^4^2
